Jpmorgan Chase & CO Solid Biosciences Inc. Transaction History

Jpmorgan Chase & CO

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$0.51 - $7.56 $838 - $12,428	1,644 Added 34.5%	6,409 $3,000
Q2 2022 Aug 11, 2022	SELL	$0.43 - $1.24 $15,593 - $44,966	-36,263 Reduced 88.39%	4,765 $3,000
Q1 2022 May 11, 2022	SELL	$0.74 - $1.79 $27,026 - $65,374	-36,522 Reduced 47.09%	41,028 $50,000
Q4 2021 Feb 10, 2022	BUY	$1.69 - $2.46 $92,289 - $134,338	54,609 Added 238.04%	77,550 $136,000
Q3 2021 Nov 12, 2021	BUY	$2.38 - $3.77 $54,599 - $86,487	22,941 New	22,941 $55,000

Ticker SLDB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 7,533,080
Market Cap $53.2M
Description
Solid Biosciences Inc. engages in developing therapies for duchenne muscular dystrophy in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophin protein expression in patients' muscles; and SGT-003, a ext-generation gene transfer candid...

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

Stay updated on Jpmorgan Chase & CO with notifications on news.